Squarepoint Ops LLC Makes New $93,000 Investment in Kronos Bio, Inc. (NASDAQ:KRON)

Squarepoint Ops LLC purchased a new position in shares of Kronos Bio, Inc. (NASDAQ:KRON) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 98,420 shares of the company’s stock, valued at approximately $93,000. Squarepoint Ops LLC owned approximately 0.16% of Kronos Bio at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of KRON. Kennedy Capital Management LLC raised its holdings in shares of Kronos Bio by 8.7% during the fourth quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company’s stock valued at $142,000 after acquiring an additional 12,007 shares during the last quarter. Gilead Sciences Inc. acquired a new position in shares of Kronos Bio during the fourth quarter valued at approximately $179,000. Peapod Lane Capital LLC acquired a new position in shares of Kronos Bio during the fourth quarter valued at approximately $534,000. Tang Capital Management LLC acquired a new stake in shares of Kronos Bio in the fourth quarter valued at approximately $953,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Kronos Bio by 19.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,171,808 shares of the company’s stock valued at $1,113,000 after purchasing an additional 192,754 shares during the last quarter. Hedge funds and other institutional investors own 64.09% of the company’s stock.

Kronos Bio Stock Performance

NASDAQ:KRON opened at $0.87 on Tuesday. The stock has a 50 day moving average price of $0.77 and a 200 day moving average price of $0.89. The stock has a market cap of $53.04 million, a PE ratio of -0.61 and a beta of 1.63. Kronos Bio, Inc. has a one year low of $0.65 and a one year high of $1.60.

Kronos Bio (NASDAQ:KRON) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.13). The firm had revenue of $2.27 million for the quarter, compared to analysts’ expectations of $1.00 million. Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%. As a group, analysts predict that Kronos Bio, Inc. will post -1.36 earnings per share for the current fiscal year.

Kronos Bio Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.